Tagged with PR

Poland Sabina Sampławska, director, head of life sciences at KPMG Poland, discusses the challenge of pricing pressures and how their innovative services help companies manage this trend, as well as the need for data transparency in constructing correct strategies for clients. She also highlights the role KPMG is playing in bringing…

Brazil Josiel Florenzano, managing director of Lundbeck Brazil and South Cone, provides us with an overview of the main dynamics shaping the Brazilian CNS market as well as the opportunities he identifies to further increase awareness and improve market access in the mental health area. You took over the helm of…

Switzerland Petra Exner and Tobias Haber discuss the unique service offering of INSIGHT Health, one of the leading data providers to the healthcare market, the company’s successful internationalization strategy, and why INSIGHT Health is the partner of choice. Could you begin by introducing INSIGHT Health to our international audience? “We should…

Poland Marcin Czech, deputy minister and undersecretary of state at the Polish Ministry of Health, provides an in-depth perspective on Poland’s drug policy framework and the new medicines policy that aims to integrate pharmacoecomonics to ensure Poland can find an efficient balance between innovative and generic treatments for long-term stability. Furthermore,…

Switzerland Rocco Donnino, executive vice president of corporate development of AppRiver AG, a cybersecurity company with headquarters in Switzerland and Florida, US, discusses the strategic steps in establishing AppRiver across Europe and the services they provide, specifically the layered security approach portrayed throughout the healthcare and life science sector. Furthermore, he…

Ukraine Ukraine’s bold decision to outsource public procurement of medicines to international agencies to combat rampant corruption has been well received by the pharma MNCs operational in the country, but faces criticism from domestic players. “Healthcare procurement was widely considered as one of the areas most seriously altered by corruption” Tetiana…

Switzerland Thomas Huber, CEO of Skan Group in Switzerland, a global leader in clean room equipment for the life sciences industry, discusses adapting to an ever-changing regulatory environment, Skan’s unique solutions, and its steadily-increasing international footprint. You joined Skan AG 21 years ago, gradually making it up to the top position…

Austria Christoph Sauermann, managing director of Mediclass, an innovative healthcare center, discusses how the complexities of the Austrian healthcare system can be solved through primary healthcare centers, such as Mediclass. Furthermore, he gives an overview of the diverse services Mediclass offers to individuals and employers, ensuring patients receive rapid access to…

Bulgaria Gergana Semova and Petko Konakchiev, founders of PharmDedict, share an overview of the Bulgarian regulatory dynamism, the reasons why healthcare companies should continue investing in the country, and explain why PharmDedict is not only a service provider, but also a solutions provider. After having worked for several years in the…

Tunisia Haithem Boukhari, CEO of medtech manufacturer Boukhari Prince Médical, documents the favorable business environment in Tunisia that has allowed him to grow the company’s production site tenfold in the last 15 years, as well as its Middle Eastern and South American ambitions. What are Boukhari Prince Medical’s main activities? “Boukhari…

Tunisia Ramzi Lebbi, general director and co-founder of mc PHARMA, a Tunisian medical information and promotion agency, describes the company’s evolution since its foundation 15 years ago, its service provider activities for multinational companies, and the potential expansion of its portfolio of services. Mr. Lebbi, looking back at mc PHARMA’s creation,…

Austria David Kasper, CEO of ARCHIMEDlife, an innovative Austrian company focused on novel laboratory diagnostics, discusses the innovative solution of a dried blood sample in daily routine diagnostics and novel assays as well as the intricacies of working in rare diseases. Furthermore, he provides an insight into the company’s legacy project…